Mirimus

Our CEO, Prem Premsrirut, is speaking on a panel session at ! "Immune System Biomarkers: Can Our Antibodies Predict How We Will React to Disease and Immunotherapy?" Thursday, June 6 at 9:00 AM - 10:00 AM in Room 26A. Don't miss it!

Meet our CEO, Prem Premsrirut, at ! Connect with us in the BIO One-on-One Partnering system or message us directly. See you there!

A major breakthrough in liver tumor and acute chronic liver diseases treatment was just published in Cell Journal. The article covers the development of HRX-215, a new MKK4 inhibitor, which reached human trials by earlier preclinical research using Mirimus' cutting-edge RNAi technology. Read more about our contribution here:

https://www.prweb.com/releases/mirimus-rnai-technology-helps-advance-new-treatment-for-liver-tumors-and-acute-chronic-liver-diseases-302090690.html

#

Join our CEO, Prem Premsrirut, at , a global gathering of visionary leaders shaping the future of biotechnology and life sciences. Connect with us to explore potential collaborations and drive innovation together.

Our CEO, Prem Premsrirut, is attending !
Look for Mirimus in the Partnering System to explore collaboration opportunities with us. Let's connect and meet at the world's premier biopharm event, where the global scientific community converges.

Our hearts are heavy as we witness the wildfires ravaging the breathtaking landscapes and communities of Maui.

In these trying times, we extend our deepest sympathies and wishes for safety to all affected. While we can't undo the devastation, we are confident in the resilience of the island's people.

The journey to healing and rebuilding may be long, but together, the spirit of aloha will prevail. If you'd like to support the people in need in Maui, please visit https://ow.ly/Qb6a50PxHl7.

May the winds of change bring you relief. Aloha!

When your immune system can't tell the difference between 'friend' and 'foe'!

The scene is set within the human body, where a battle is about to unfold. On one side, we have the immune system. Its mission is to protect the body from harmful invaders, the pathogens. This pathogen has craftily disguised itself to look similar to the body's own cells. As a result, the antibody find itself scratching its head in confusion. It can't distinguish between the genuine 'self' cells and the devious invaders due to their shared molecular traits, represented in the cartoon by the pink antigens. This phenomenon is called molecular mimicry. When the immune system struggles to differentiate between friend and foe, it can mistakenly attack the body's own tissues, leading to various autoimmune disorders.

Mirimus is unraveling the mysteries of molecular mimicry and its role in autoimmune diseases. Through our cutting-edge research, they aim to shed light on the intricate mechanisms behind these disorders, paving the way for potential breakthroughs in diagnosis and treatment.

Credits: cartoon by Creative Med Doses

Envision the limitless possibilities when we unite. Join us at Biotechnology Innovation Organization - BIO International Convention from June 5th-8th. Look for Mirimus in the Bio Partnering System to explore collaboration opportunities with us. Let's connect and meet at the world's premier biotech event, where the global biotech community converges!

Did you know that human beings share an astonishing 99.9% genetic similarity? It's remarkable to think about the profound commonality that binds us all. However, it's the minuscule 0.1% that makes each one of us unique and can unlock clues to unraveling the mysteries of diseases.

At Mirimus, we are motivated by the pursuit of understanding the genetic basis of diseases, fueling groundbreaking research, and advancing healthcare. Our scientists strive to discover new drug targets and therapeutics to pave the way for innovations that can transform the lives of each one of us.

70 years ago, on April 25 1953, Watson and Crick formally proposed the DNA double helix model in a one-page paper, with the understated title "A Structure for Deoxyribose Nucleic Acid” in Nature. The two scientists would get the Nobel Prize in 1962.

The discovery of the double helix was a monumental breakthrough in biology which has led to a greater understanding of the genetic basis for many diseases, as well as potential new treatments.

Read Watson and Crick’s full paper here: http://ow.ly/jOSJ50NRsEL

Giuseppe Militello, our Associate Director of RNAi Therapeutics, is attending the 8th Cold Spring Harbor Laboratory meeting on Nucleic Acid Therapies. The conference brings together a diverse group of scientists studying the development of RNA and other oligonucleotide-based therapeutic approaches.

Giuseppe is looking forward to engaging with other scientists to discuss the current challenges and advancements in the development of RNA-based therapeutics, as well as potential areas of collaboration and innovation in this field.

EXCITING NEWS! We are thrilled to announce the launch of our brand-new website!
We now have a fresh look that highlights our scientific expertise and our cutting-edge health solutions. Our new website provides sharp insight into our passions: drug discovery, molecular diagnostics, and therapeutics, outlining what we’ve accomplished so far and what the future holds for us. Check us out at www.mirimus.com and let us know what you think in the comments!

We first made it to stage, now we made it to the big screen! We're incredibly excited to be featured in Broadway Rising, a documentary which details the Broadway community's painful and inspirational journey back to the stage following the COVID-19 shutdown on March 12, 2020. Over 96,000 people lost their jobs when the pandemic hit Broadway, destroying an entire ecosystem of enterprises supporting the industry. Despite these unprecedented circumstances, the show must go on! Broadway Rising shines a spotlight on the experiences of those who struggled, persisted, and ultimately succeeded on the eagerly anticipated reopening night, September 14, 2021. Mirimus is proud to be part of this story. We are the chosen COVID-19 testing provider of many Broadway shows helping to prevent production shutdowns and protect their cast and crew.

Official trailer: https://www.youtube.com/watch?v=hw9caxHrqnU

We are looking for a highly motivated, hard-working, and independent chemist who is interested in the field of biosensing for next-generation diagnostics. Sounds like a good fit for you? Apply now!

Full job description: https://www.linkedin.com/jobs/view/3300952552/

Six has been an enormous success at Broadway! We are proud to be their chosen company to prevent production shutdowns and protect their cast and crew with on-site COVID-19 testing. Looking for ways to prevent COVID outbreaks in your set? Reach out to us!

Aloha! Mirimus hosted a Hawaiian luau reception for the 14th Biennial Meeting on Mechanisms & Models of Cancer at Cold Spring Harbor Laboratory. After days of insightful seminars, speakers, and workshops, the Mirimus luau was the perfect time to show appreciation for all the scientist in attendance with an opportunity to exhale, unwind, and socialize. The images speak for themselves! Share your pictures of the party and tag !

Prem Premsrirut (CEO) and Rosaline Sun (Senior Scientist) attended the 14th Biennial Meeting on Mechanisms & Models of Cancer at Cold Spring Harbor Laboratory. The conference brought together a diverse group of scientists studying various molecular, genetic, biochemical and animal model approaches to the analysis of cancer.

After such an intense week, we are excited to host an epic event at Cold Spring Harbor Laboratory this Friday! Come enjoy with us!

We are proud to announce our partnership with NYU Tandon School of Engineering , one of the world’s leading engineering schools.

Mirimus and NYU will strive to create new microchips that can be embedded in wearable devices to monitor a variety of human health threats, helping people make better, faster and more complete decisions about their health in ways that fit easily into their lives. With the right tools, we can give everyone the best chance to live a healthier life. And we’re putting more power, control, ease, and convenience in the hands of the people who matter most and who have the most at stake — the patients.

Learn more about our partnership here ⬇️
https://tinyurl.com/2p9rxye8

We’re always looking for exciting new ideas and we love working together with passionate scientists. Interested in collaborating with us? Reach out!

Giuseppe Maria de Peppo (Director of Internal Research) attended Wearable Technologies Conference in San Francisco, the number one event for decision-makers, techpreneurs and researchers to gain insights on wearable innovations.

He was inspired and amazed by how the next wave of smart medical wearables will revolutionize healthcare and dramatically improve quality of life. If you were at the conferences and we didn’t have the chance to meet there, reach out to us! We are looking forward to cementing new partnerships.

Prem Premsrirut (CEO) and Anand Agarwal (Head of Molecular Diagnostics) attended American Association for Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo and SalivaDirect First Annual Conference in Chicago, where they connected with global leaders in molecular diagnostics and attended scientific sessions about innovations in laboratory medicine.

They met brilliant people who explore the very latest advancements in clinical laboratory science and healthcare.

If you were at the conferences and we didn’t have the chance to meet there, reach out to us! We are looking forward to cementing new partnerships.

🧬Mirimus brings RNAi technology to its peak. But what is RNAi after all? 🤔

Every high school biology student learns the basics of how genes are expressed: DNA, the cell’s master information keeper, is copied into messenger RNA, which carries protein-building instructions to the ribosome, the part of the cell where proteins are assembled.

But it turns out the picture is far more complicated than that. In recent years, biologists have discovered a myriad of other molecules that fine-tune this process, including several types of RNA. Through a naturally occurring phenomenon known as RNA interference (RNAi), short strands of RNA can selectively intercept and destroy messenger RNA before it delivers its instructions.

Scientists are now pursuing disease treatments based on RNAi, which offers the tantalizing ability to shut down any gene in the body. Indeed, such molecules are now employed for the development of vaccines, regulation of the gene expression, and creation of aptamers binding specific targets. Mirimus Therapeutics department aims to harness the power of the RNAi machinery to develop novel and highly specific treatments to be used in several pathological conditions. Thanks to our broad expertise in RNAi, we are able to generate artificial microRNAs with enhanced processing and specificity to precisely target and efficiently silence genes that are known to be detrimental in a given pathology.